PIK3CA and non-small cell lung carcinoma: Sun et al. found mutations in PTPR family genes lead to better prognosis in NSCLC patients receiving immunotherapy [37], suggesting that this may be a potential mechanism by which PI3K/Akt-MT patients have better immunotherapy efficacy.